226 related articles for article (PubMed ID: 1699279)
1. Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate.
Malspeis L; Grever MR; Staubus AE; Young D
Semin Oncol; 1990 Oct; 17(5 Suppl 8):18-32. PubMed ID: 1699279
[TBL] [Abstract][Full Text] [Related]
2. Disposition of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-phosphate in mice and dogs.
Noker PE; Duncan GF; El Dareer SM; Hill DL
Cancer Treat Rep; 1983 May; 67(5):445-56. PubMed ID: 6189605
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, bioavailability and effects on electrocardiographic parameters of oral fludarabine phosphate.
Yin W; Karyagina EV; Lundberg AS; Greenblatt DJ; Lister-James J
Biopharm Drug Dispos; 2010 Jan; 31(1):72-81. PubMed ID: 19862681
[TBL] [Abstract][Full Text] [Related]
4. 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma.
Danhauser L; Plunkett W; Keating M; Cabanillas F
Cancer Chemother Pharmacol; 1986; 18(2):145-52. PubMed ID: 2431803
[TBL] [Abstract][Full Text] [Related]
5. Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia.
Danhauser L; Plunkett W; Liliemark J; Gandhi V; Iacoboni S; Keating M
Leukemia; 1987 Sep; 1(9):638-43. PubMed ID: 3478543
[TBL] [Abstract][Full Text] [Related]
6. Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia.
Gandhi V; Kemena A; Keating MJ; Plunkett W
Cancer Res; 1992 Feb; 52(4):897-903. PubMed ID: 1737352
[TBL] [Abstract][Full Text] [Related]
7. Cellular and clinical pharmacology of fludarabine.
Gandhi V; Plunkett W
Clin Pharmacokinet; 2002; 41(2):93-103. PubMed ID: 11888330
[TBL] [Abstract][Full Text] [Related]
8. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W
Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
[TBL] [Abstract][Full Text] [Related]
9. Metabolism and action of fludarabine phosphate.
Plunkett W; Huang P; Gandhi V
Semin Oncol; 1990 Oct; 17(5 Suppl 8):3-17. PubMed ID: 1699280
[TBL] [Abstract][Full Text] [Related]
10. Effects on human peripheral lymphocytes of in vivo administration of 9-beta-D-arabinofuranosyl-2-fluoroadenine-5'-monophosphate (NSC 312887), a new purine antimetabolite.
Boldt DH; Von Hoff DD; Kuhn JG; Hersh M
Cancer Res; 1984 Oct; 44(10):4661-6. PubMed ID: 6205751
[TBL] [Abstract][Full Text] [Related]
11. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
Gandhi V; Estey E; Du M; Keating MJ; Plunkett W
Clin Cancer Res; 1997 Sep; 3(9):1539-45. PubMed ID: 9815841
[TBL] [Abstract][Full Text] [Related]
12. A comprehensive phase I and II clinical investigation of fludarabine phosphate.
Grever M; Leiby J; Kraut E; Metz E; Neidhart J; Balcerzak S; Malspeis L
Semin Oncol; 1990 Oct; 17(5 Suppl 8):39-48. PubMed ID: 1699282
[TBL] [Abstract][Full Text] [Related]
13. Pharmacology of fludarabine phosphate after a phase I/II trial by a loading bolus and continuous infusion in pediatric patients.
Avramis VI; Champagne J; Sato J; Krailo M; Ettinger LJ; Poplack DG; Finkelstein J; Reaman G; Hammond GD; Holcenberg JS
Cancer Res; 1990 Nov; 50(22):7226-31. PubMed ID: 1699658
[TBL] [Abstract][Full Text] [Related]
14. Phase I clinical investigation of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate (NSC 312887), a new purine antimetabolite.
Hutton JJ; Von Hoff DD; Kuhn J; Phillips J; Hersh M; Clark G
Cancer Res; 1984 Sep; 44(9):4183-6. PubMed ID: 6204752
[TBL] [Abstract][Full Text] [Related]
15. Termination of DNA synthesis by 9-beta-D-arabinofuranosyl-2-fluoroadenine. A mechanism for cytotoxicity.
Huang P; Chubb S; Plunkett W
J Biol Chem; 1990 Sep; 265(27):16617-25. PubMed ID: 1697861
[TBL] [Abstract][Full Text] [Related]
16. In vitro cytotoxic effects of fludarabine (2-F-ara-A) in combination with commonly used antileukemic agents by isobologram analysis.
Kano Y; Akutsu M; Tsunoda S; Suzuki K; Ichikawa A; Furukawa Y; Bai L; Kon K
Leukemia; 2000 Mar; 14(3):379-88. PubMed ID: 10720130
[TBL] [Abstract][Full Text] [Related]
17. Phase I clinical trials with fludarabine phosphate.
Von Hoff DD
Semin Oncol; 1990 Oct; 17(5 Suppl 8):33-8. PubMed ID: 1699281
[TBL] [Abstract][Full Text] [Related]
18. [Studies on pharmacokinetics of 9-beta-D-arabinofuranosyl adenine nanocapsules].
Yang TY; Hu J; Li HX
Yao Xue Xue Bao; 1992; 27(12):923-7. PubMed ID: 1299143
[TBL] [Abstract][Full Text] [Related]
19. Pharmacologic analysis of the ip administration of fludarabine phosphate in the swine.
Weiss GR; Gaskill HV; Phillips JL
Cancer Treat Rep; 1986 Apr; 70(4):499-502. PubMed ID: 2421893
[TBL] [Abstract][Full Text] [Related]
20. Encapsulation, metabolism and release of 2-fluoro-ara-AMP from human erythrocytes.
Fraternale A; Rossi L; Magnani M
Biochim Biophys Acta; 1996 Oct; 1291(2):149-54. PubMed ID: 8898876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
